Kriya Therapeutics was last valued at $200M. It dates from Jan 2021. The company is private, so there is no listed share price.
One company valuation: $200M, dated Jan 2021.
Lead investors for each round are in the funding timeline.
The closest gene therapy and biotech peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Kriya Therapeutics is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
